To Advance Next-Generation Influenza Vaccine for Pandemic and Seasonal Preparedness
Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836
Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced it has secured $19.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The multi-year agreement will support key development activities for Osivax’ lead influenza A vaccine candidate, OVX836, a next-generation, broad-spectrum vaccine designed to provide long-lasting protection against circulating and emerging influenza A strains.
“Osivax is excited to explore our universal flu vaccine approach and the potential of OVX836 to transform global influenza preparedness,” said Alexandre Le Vert, CEO & Co-Founder of Osivax. “With BARDA’s support, we are accelerating our path toward late-stage development and preparing for future large-scale efficacy trials.”
